LDOC1抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human ovarian cancer tissue using P08474(LDOC1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The LDOC1 (Leucine Zipper, Down-Regulated in Cancer 1) gene encodes a nuclear protein implicated in regulating cell proliferation and apoptosis. Initially identified as a tumor suppressor, LDOC1 expression is frequently downregulated in various cancers, including gastric, pancreatic, and breast cancers, often correlating with poor prognosis. Its precise molecular mechanisms remain under investigation, but studies suggest LDOC1 interacts with signaling pathways like NF-κB and PI3K/AKT, modulating transcriptional activity and apoptosis-related proteins such as BCL-2.

LDOC1 antibodies are essential tools for detecting LDOC1 protein expression in research and diagnostics. They enable techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence to study LDOC1's tissue distribution, expression levels in tumors versus normal tissues, and its role in cancer progression. Commercially available antibodies vary in specificity, with validation often confirmed using knockdown or knockout cell lines. Recent studies explore LDOC1's potential as a biomarker for cancer aggressiveness or therapeutic response. However, functional studies using these antibodies are limited, highlighting the need for further characterization of LDOC1's biological roles and its relevance in clinical applications.